Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial.
David R W JayneJürgen SteffgenJuanita Romero-DiazIngeborg BajemaDimitrios T BoumpasKajohnsak NoppakunHirofumi AmanoHarold Michael GomezBancha SatirapojYingyos AvihingsanonRatana ChawanasuntorapojMagdalena MaderoBeata NaumnikRhona RectoNora FaganIvette RevolloJing WuSudha VisvanathanRichard A FuriePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
The trial failed to demonstrate a dose-response relationship for the primary CRR endpoint. Post-hoc analyses suggest a potential benefit of BI 655064 180mg in patients with active LN. This article is protected by copyright. All rights reserved.